Patent · US Active

CLEC11A is a bone growth agent

US11890320B2 · kind B2 · utility

0Cited by

113References

10Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Sean Morrison · Ann Arbor, US
Rui Yue · Dallas, US

Key dates

Filing date	May 1, 2020
Grant date	Feb 6, 2024
Priority date	—
Expiry date	Oct 5, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.